While the pricing structure is similar across all three, coverage tends to be more consistent when semaglutide is prescribed for type 2 diabetes than for weight management, which is why out-of-pocket costs can vary even though all three medications have the same active ingredient
Each has somewhat different kinetics with different parameters: UGT3 has simple Michaelis-Menten kinetics
Effect of Semaglutide on the Risk of Hyperthyroidism in Patients with Type 2 Diabetes: PIONEER 6 Subanalysis
Frequently Asked Questions As of July 2026, retatrutide has completed four Phase 3 readouts: TRIUMPH-4 (28.7% weight loss in knee OA population, December 2025), TRIUMPH-1 (28.3% weight loss in 2,339 general obesity patients, May 2026), TRANSCEND-T2D-1 (-2.0% HbA1c and 16.8% weight loss in 537 T2D patients, June 2026), and the TRIUMPH-1 sleep apnea substudy (60.6% AHI reduction, June 2026)
LEAD-4 Study Investigators